Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

Pegfilgrastim is indicated for reducing the duration of neutropenia and incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy. Here, safety and efficacy of MYL-1401H, a proposed pegfilgrastim biosimilar, were investigated as prophylaxis for chemotherapy-induced neutropenia. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Waller, Cornelius F., Ranganna, Gopinath M., Pennella, Eduardo J., Blakeley, Christopher, Bronchud, Miguel H., Mattano Jr, Leonard A., Berzoy, Oleksandr, Voitko, Nataliia, Shparyk, Yaroslav, Lytvyn, Iryna, Rusyn, Andriy, Popov, Vasil, Láng, István, Beckmann, Katrin, Sharma, Rajiv, Baczkowski, Mark, Kothekar, Mudgal, Barve, Abhijit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469669/
https://www.ncbi.nlm.nih.gov/pubmed/30824956
http://dx.doi.org/10.1007/s00277-019-03639-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469669/
https://www.ncbi.nlm.nih.gov/pubmed/30824956
http://dx.doi.org/10.1007/s00277-019-03639-5

Ejemplares similares